PAVmed (PAVM) Cash & Equivalents (2015 - 2025)

PAVmed has reported Cash & Equivalents for 11 years, with the latest figure at $1.5 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 26.58% year-over-year to $1.5 million; the trailing twelve-month figure through Dec 2025 stood at $1.5 million (up 26.58% YoY), and the FY2025 full-year result was $1.5 million, up 26.58% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $1.5 million, down from $3.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $77.3 million in Q4 2021, with the low at $1.2 million in Q4 2024.
• Average Cash & Equivalents over 5 years is $32.3 million, with a median of $31.8 million recorded in 2023.
• Year-over-year, Cash & Equivalents surged 510.31% in 2021 and sank 93.97% in 2024.
• Tracing PAVM's Cash & Equivalents over 5 years: stood at $77.3 million in 2021, then tumbled by 48.56% to $39.7 million in 2022, then slumped by 50.59% to $19.6 million in 2023, then slumped by 93.97% to $1.2 million in 2024, then increased by 26.58% to $1.5 million in 2025.
• The last three Cash & Equivalents figures came in at $1.5 million (Q4 2025), $3.1 million (Q3 2025), and $4.0 million (Q2 2025), per Business Quant data.

Peer Comparison